Abstract:Multiple sclerosis (MS) is characterized by autoimmune inflammation and subsequent neurodegeneration. It is believed that early in the disease course, proinflammatory T cells that are activated in the periphery by antigen presentation cross the blood-brain barrier (BBB) into the CNS directed by various chemotaxic agents. However, to date, there has been no formal demonstration of a specific precipitating antigen. Once inside the CNS, activated T cells including T helper-1 (Th1), Th17, γδ and CD8+ types are believed to secrete proinflammatory cytokines. Decreased levels of Th2 cells also correlate with relapses and disease progression in MS, since Th2-derived cytokines are predominantly anti-inflammatory. In healthy tissue, inflammatory effects are opposed by specific subsets of regulatory T cells (Tregs) including CD4+, CD25+ and FoxP3+ cells that have the ability to downregulate the activity of proinflammatory T cells, allowing repair and recovery to generally follow inflammatory insult. Given their function, the pathogenesis of MS most likely involves deficits of Treg function, which allow autoimmune inflammation and resultant neurodegeneration to proceed relatively unchecked.Interferons (IFNs) are naturally occurring cytokines possessing a wide range of anti-inflammatory properties. Recombinant forms of IFNβ are widely used as first-line treatment in relapsing forms of MS. The mechanism of action of IFNb is complex, involving effects at multiple levels of cellular function. IFNβ appears to directly increase expression and concentration of anti-inflammatory agents while downregulating the expression of proinflammatory cytokines. IFNβ treatment may reduce the trafficking of inflammatory cells across the BBB and increase nerve growth factor production, leading to a potential increase in neuronal survival and repair. IFNβ can also increase the number of CD56bright natural killer cells in the peripheral blood. These cells are efficient producers of anti-inflammatory mediators, and may have the ability to curb neuron inflammation. The mechanistic effects of IFNβ manifest clinically as reduced MRI lesion activity, reduced brain atrophy, increased time to reach clinically definite MS after the onset of neurological symptoms, decreased relapse rate and reduced risk of sustained disability progression.The mechanism of action of IFNβ in MS is multifactorial and incompletely understood. Ongoing and future studies will increase our understanding of the actions of IFNβ on the immune system and the CNS, which will in turn aid advances in the management of MS.

The Effect of Interferon Beta and Natalizumab on miR-20b Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Potentially Mediated by Modulation of the Jak-STAT Signaling Pathway: A Case-control Study

Effect of Interferon-Beta Treatment on the Proportion of Th17 Cells and Related Cytokines in Multiple Sclerosis: A Meta-Analysis.

Decreased Serum IL-22 Levels in Patients with Systemic Lupus Erythematosus

Profiles of miRNA expression and IFN-γ serum level as biomarker for the development of Multiple Sclerosis

The frequencies of peripheral blood CD5+CD19+ B cells, CD3−CD16+CD56+ NK, and CD3+CD56+ NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder

Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS

IFN-β Induces the Proliferation of CD4+CD25+Foxp3+ Regulatory T Cells Through Upregulation of GITRL on Dendritic Cells in the Treatment of Multiple Sclerosis

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis

Regulatory Effects of IFN‐β on Production of Osteopontin and IL‐17 by CD4+ T Cells in MS

Preliminary Study: Treatment with Intramuscular Interferon Beta-1A Results in Increased Levels of IL-12Rβ2+ and Decreased Levels of IL23R+ CD4+ T - Lymphocytes in Multiple Sclerosis

Identification of Monotonically Differentially Expressed Genes for IFN-β-Treated Multiple Sclerosis Patients

IFN-β Acts on Monocytes to Ameliorate CNS Autoimmunity by Inhibiting Proinflammatory Cross-Talk Between Monocytes and Th Cells.

Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy

The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

Inhibitory Effect of IFNβ-1b on the Expression of C-C Chemokines Mrna in Patients with Multiple Sclerosis

Vitamins A and D Enhance the Expression of Ror-γ-Targeting miRNAs in a Mouse Model of Multiple Sclerosis

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment

Altered Expression of B Cell Receptor Signaling Pathway Genes in Peripheral Blood of Patients with Multiple Sclerosis

The immunomodulatory effects of all-trans retinoic acid and docosahexaenoic acid combination treatment on the expression of IL-2, IL-4, T-bet, and GATA3 genes in PBMCs of multiple sclerosis patients

Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment

Altered gene expression of miR-155 in peripheral blood mononuclear cells of Multiple sclerosis patients: Correlation with TH17 frequency, inflammatory cytokine profile and autoimmunity